Enhancing Knowledge of Small Cell Lung Cancer Treatment and Management

An educational activity offered by i3 Health has provided significant knowledge gains regarding strategies to enhance the clinical outcomes of patients with extensive-stage small cell lung cancer (SCLC) Among the 238,340 new cases of lung cancer reported in the United States each year, approximately 14% of cases are classified as small cell, a more aggressive subtype compared with its non–small cell counterpart. Most patients present with advanced or metastatic disease, making systemic therapy t...

Continue reading

Hopeful Developments in the Survival Rate for Patients With Extensive-Stage Small Cell Lung Cancer: Insights from Anne Chiang, MD, PhD

Anne Chiang, MD, PhD.

Patients with extensive-stage small cell lung cancer (SCLC) are experiencing better survival rates than they have in past years. In honor of Lung Cancer Awareness Month, Anne Chiang, MD, PhD, Chief Integration Officer and Deputy Chief Medical Officer of Smilow Cancer Hospital and Associate Professor in the Section of Medical Oncology at Yale School of Medicine, discusses recent developments that have led to improvements in survival rates, as well as also exciting new developments to come in the treatment of patients with extensive-stage small cell lung cancer.

Continue reading

Lurbinectedin Approved: Metastatic Small-Cell Lung Cancer

The FDA has granted accelerated approval to lurbinectedin (ZepzelcaTM, Pharma Mar, S.A.) for adults with metastatic small-cell lung cancer (SCLC) experiencing disease progression on or after platinum-based chemotherapy. The efficacy of lurbinectedin, a selective inhibitor of oncogenic transcription, was investigated in a multinational, single-arm, open-label phase 2 basket trial, PM1183-B-005-14 (Study B-005; NCT02454972), which enrolled adults with SCLC previously treated with only one chemothe...

Continue reading

Racial, Age-Related Disparities in Lung Cancer Treatment

A new study reports that only 62.1% of US patients with lung cancer receive treatment that adheres to guidelines, and elderly and non-Hispanic black patients are disproportionately represented among those whose cancer is undertreated. For the study, now published in Annals of the American Thoracic Society, the researchers evaluated whether 441,812 lung cancer cases in the US National Cancer Database diagnosed between 2010 and 2014 received treatment that adhered to the National Comprehensive Can...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.